Even Lower Doses of Semaglutide Improve Inflammation and Metabolism in Obesity | Research

The takeaway

Submaximal semaglutide doses combined with diet and exercise improved metabolic profiles and reduced inflammation markers in 32 obese patients over 12 weeks.

Mean BMI 40.5
Even in severely obese patients, submaximal semaglutide doses combined with lifestyle changes produced measurable metabolic improvements

What the researchers found

Submaximal doses of semaglutide combined with lifestyle modifications improved metabolic markers and obesity-related inflammation biomarkers over 12 weeks.

Why it matters

Many patients cannot tolerate maximum semaglutide doses due to side effects. Showing that lower doses still provide metabolic benefits gives clinicians confidence to use doses that patients can actually maintain.

The numbers in context

32 patients (11 men, 21 women, mean age 49, mean BMI 40.5). 12-week treatment with submaximal semaglutide. Significant reductions in weight, insulin, leptin, ferritin, resistin, IL-6, TNF-alpha, and PAI-1.

How the study worked

Prospective observational study of 32 adults (11 men, 21 women; mean BMI 40.5; mean age 49) treated with submaximal semaglutide plus hypocaloric diet and increased physical activity over 12 weeks.

Who was studied

Obese adults (BMI ~40) treated with submaximal semaglutide

What this study cannot tell us

Small sample (n=32), no control group, and short 12-week duration. Cannot separate the effects of semaglutide from those of diet and exercise changes.

How to read the evidence

Observational study without a control group — the improvements could be partly or wholly due to dietary and exercise changes. A randomized controlled trial would be needed for definitive conclusions.

When this study was published

Published in 2025, contributing real-world evidence on lower-dose semaglutide effectiveness.

The bigger picture

This supports a more nuanced approach to GLP-1 dosing — rather than pushing all patients to maximum doses, lower doses combined with lifestyle changes may provide sufficient metabolic improvement with better tolerability.

Questions still open

How do submaximal dose results compare to full-dose semaglutide outcomes in matched populations?
Are the inflammatory improvements sustained beyond 12 weeks at submaximal doses?

Common questions

Can lower doses of semaglutide still help with obesity?

This study suggests yes. Even submaximal doses improved metabolic and inflammatory markers when combined with diet and exercise, potentially offering a better-tolerated option for patients who cannot handle the full dose.

What are adipocytokines?

Adipocytokines are signaling molecules released by fat tissue that regulate inflammation, metabolism, and appetite. In obesity, these markers are often abnormal, contributing to metabolic dysfunction and chronic low-grade inflammation.

Read the original research

Effect of Submaximal Doses of Semaglutide in Patients with Obesity on Metabolic Profile and Serum Levels of Adipocytokines.

Pharmaceuticals (Basel, Switzerland), 18(9)

View on PubMed ↗Publisher’s paper ↗

Citation

Péč, Martin Jozef; Jurica, Jakub; Péčová, Monika; Nagy, Norbert; Focko, Boris; Miertová, Zuzana; Ferencová, Nikola; Ságová, Ivana; Tonhajzerová, Ingrid; Bolek, Tomáš; Galajda, Peter; Mokáň, Marián; Samoš, Matej. (2025). Effect of Submaximal Doses of Semaglutide in Patients with Obesity on Metabolic Profile and Serum Levels of Adipocytokines.. Pharmaceuticals (Basel, Switzerland), 18(9). https://doi.org/10.3390/ph18091364